[8-K] Silexion Therapeutics Corp Reports Material Event

Rhea-AI Filing Summary

Form 8-K, Item 7.01 – Regulation FD. On 31 Jul 2025 Silexion Therapeutics Corp (SLXN) furnished a press release titled “Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation.” The release describes laboratory findings that achieved up to 97 % inhibition of cancer-cell proliferation and activity against a novel KRAS mutation.

The disclosure is expressly “furnished” rather than “filed,” shielding it from Exchange Act §18 liability and preventing automatic incorporation into Securities Act filings. No financial metrics, clinical-trial results, regulatory milestones, or transactional details accompanied the announcement. Exhibit 99.1 contains the press release; Exhibit 104 is the Inline XBRL cover page. Ordinary shares (SLXN) and high-strike warrants (SLXNW) remain listed on Nasdaq.

Investor takeaway: Encouraging preclinical signal but very early in the development cycle; there is no immediate effect on revenue, guidance, or balance-sheet items.

Insights

Biotech Equity Analyst

TL;DR: Strong lab signal, yet preclinical; valuation impact limited until clinical data emerge.

The 8-K merely furnishes a press release with up to 97 % growth inhibition against cancer cells, including a previously untested KRAS variant. While mechanistically exciting, the data are confined to the preclinical stage, offering no insight into pharmacokinetics, safety, or human efficacy. Because the information is furnished, management signals that this is an early scientific update, not a material financial event. Near-term cash flows, trial timelines, and regulatory pathways remain undisclosed. As such, the announcement is scientifically positive but financially neutral.

Risk Analyst

TL;DR: Early promise, high execution risk; no change to financial risk profile.

Investors should note that high-strike warrants ($1,552.50) imply deep out-of-the-money optionality, reflecting speculative upside rather than imminent dilution. The absence of clinical or regulatory guidance means development, funding, and approval risks are unchanged. The filing’s ‘furnished not filed’ status underscores management’s intent to avoid legal liability for forward-looking scientific claims, reinforcing the preliminary nature of the data.

false000202241600-0000000972NASDAQNASDAQ00020224162025-07-312025-07-310002022416slxn:OrdinarySharesParValue00135PerShareMember2025-07-312025-07-310002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2025-07-312025-07-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 31, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-7564999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 31, 2025, Silexion Therapeutics Corp issued a press release entitled “Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation.” A copy of the press release is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits 

(d) Exhibits

99.1		Press Release dated July 31, 2025
104		Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: July 31, 2025	/s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

FAQ

What did Silexion Therapeutics (SLXN) announce in its 8-K?

The company furnished a press release showing up to 97 % preclinical inhibition of cancer cell growth, including results on a new KRAS mutation.

Does the 8-K include any financial results or guidance for SLXN?

No. The filing contains no financial statements, earnings data, or guidance; it is limited to scientific findings.

Is the disclosed information considered filed with the SEC?

No. Under Item 7.01 it is furnished, not filed, and therefore not subject to Exchange Act §18 liability.

How might the preclinical data affect SLXN’s valuation?

While scientifically encouraging, the data are early-stage; valuation impact will depend on future clinical confirmation.

What securities does SLXN have listed on Nasdaq?

SLXN lists Ordinary Shares (SLXN) and warrants (SLXNW) exercisable at $1,552.50 per share.